MOUNTAIN VIEW, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) — Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced preliminary unaudited operational and financial results for the fourth quarter and full year ended January 3, 2026.
Fourth Quarter 2025 Results
- Total revenue is expected to be between $14.6 million and $14.8 million compared to $12.7 million in the prior year quarter, representing year-over-year growth between 15% and 17%
- Achieved positive cash flow in the fourth quarter
- Sold 15,800 Cyclo G6® probes compared to 13,300 in the prior year quarter
- Sold 44 Cyclo G6 Glaucoma Laser Systems, compared to 47 in the prior year quarter
Full Year 2025 Results
- Total revenue is expected to be between $52.5 million and $52.7 million compared to $48.7 million in 2024, representing year-over-year growth of 8%
- The company expects to achieve positive adjusted EBITDA in 2025
- Sold 57,700 Cyclo G6® probes, compared to 55,400 in the prior year
- Sold 133 Cyclo G6® Glaucoma Laser Systems compared to 125 in the …